Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zealand Pharma has announced positive results on lixisenatide (Lyxumia1)) for the treatment of type 2 diabetes.
Subscribe to our email newsletter
Lixisenatide QD had a greater post-prandial glucose lowering (PPG) effect than liraglutide QD in patients with Type 2 diabetes (-129% versus -41%, respectively).
It is accompanied by significant decreases in insulin, C-peptide and glucagon and a better gastro-intestinal tolerability profile.
Add-on treatment with lixisenatide (once-daily) provided an improvement in postprandial glycemic control over 24 weeks in Type 2 diabetes patients insufficiently controlled on SU +/- metformin.
Lixisenatide also reduced glucagon and pro-insulin and thus improved glucose homeostasis.
In the present animal studies, lixisenatide and liraglutide had a different impact on post-prandial carbohydrate utilization, with lixisenatide having a stronger prandial effect than liraglutide.
This potent effect of lixisenatide on post-meal glucose control might result in improvement of glucose control in Type 2 diabetes, allowing more patients to reach their HbA1c target with body weight loss.